BusinessCombination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical TrialsBy Nasdaq OMXFeb 7, 2017, 9:40 PM UTC
